Evidence map›Paper›PMID 37840499›Full record

ArticleJournal of Alzheimer's disease : JAD2023

Multi-Site Cross-Site Inter-Rater and Test-Retest Reliability and Construct Validity of the MarkVCID White Matter Hyperintensity Growth and Regression Protocol.

Ahmed A Bahrani, Erin L Abner, Charles S DeCarli, Justin M Barber, Abigail C Sutton, Pauline Maillard, Francisco Sandoval, Konstantinos Arfanakis, Yung-Chuan Yang, Arnold M Evia and 24 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 12 institutions in 1 country.

Ahmed A BahraniDepartment of Neurology, University of Kentucky, College of Medicine, Lexington, KY, USA.
Erin L AbnerSanders-Brown Center on Aging, University of Kentucky, College of Medicine, Lexington, KY, USA.
Charles S DeCarliDepartment of Neurology, University of California, Davis, CA, USA.
Justin M BarberSanders-Brown Center on Aging, University of Kentucky, College of Medicine, Lexington, KY, USA.
Abigail C SuttonSanders-Brown Center on Aging, University of Kentucky, College of Medicine, Lexington, KY, USA.
Pauline MaillardDepartment of Neurology, University of California, Davis, CA, USA.
Francisco SandovalDepartment of Neurology, University of California, Davis, CA, USA.
Konstantinos ArfanakisRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Yung-Chuan YangRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Arnold M EviaRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Julie A SchneiderRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Mohamad HabesResearch Imaging Institute, University of Texas Health San Antonio, San Antonio, TX, USA.
Crystal G FranklinResearch Imaging Institute, University of Texas Health San Antonio, San Antonio, TX, USA.
Sudha SeshadriGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, TX, USA.
Claudia L SatizabalGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, TX, USA.
Arvind CaprihanThe Mind Research Network, Albuquerque, NM, USA.
Jeffrey F ThompsonThe Mind Research Network, Albuquerque, NM, USA.
Gary A RosenbergCenter for Memory and Aging, University of New Mexico, Health Sciences Center, Albuquerque, NM, USA.
Danny J J WangDepartments of Neurology and Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Kay JannDepartments of Neurology and Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Chenyang ZhaoDepartments of Neurology and Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Hanzhang LuDepartment of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Marilyn S AlbertDepartment of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Doaa G AliSanders-Brown Center on Aging, University of Kentucky, College of Medicine, Lexington, KY, USA.
Herpreet SinghDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Kristin SchwabDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Steven M GreenbergDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Karl G HelmerDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
David K PowelDepartment of Neuroscience, University of Kentucky, College of Medicine, Lexington, KY, USA.
Brian T GoldSanders-Brown Center on Aging, University of Kentucky, College of Medicine, Lexington, KY, USA.
Larry B GoldsteinDepartment of Neurology, University of Kentucky, College of Medicine, Lexington, KY, USA.
Donna M WilcockSanders-Brown Center on Aging, University of Kentucky, College of Medicine, Lexington, KY, USA.
Gregory A JichaDepartment of Neurology, University of Kentucky, College of Medicine, Lexington, KY, USA.
University of Kentucky · USRush University Medical Center · USMassachusetts General Hospital · USThe University of Texas Health Science Center at San Antonio · USUniversity of California, Davis · USUniversity of Southern California · USJohns Hopkins Medicine · USMind Research Network · USHarvard University · USInstitute for Neurodegenerative Disorders · USJohns Hopkins University · USUniversity of New Mexico · US

Funding

UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI OLICHNEY, JOHN M · 1991 to 2020
$28.3M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Mohamad Habes · 2021 to 2026
$24.0M
University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
VCID Biomarkers Coordinating CenterU24NS100591 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Steven M Greenberg · 2016 to 2026
$19.8M
Validation of Biomarkers of Small Vessel Injury in VCIDUF1NS100598 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ROSENBERG, GARY ALLEN · 2021 to 2023
$6.3M
The University of Kentucky MarkVCID Biomarker Validation Cohort: Development of a Toolbox to Advance VCID Interventional StudiesUF1NS125488 · NINDS · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, WILCOCK, DONNA M · 2021 to 2023
$6.1M
Novel imaging and endothelial biomarkers of small vessel cerebrovascular diseaseUH3NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DECARLI, CHARLES, KRAMER, JOEL H · 2018 to 2020
$3.5M
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementiaU01NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2023 to 2025
$3.5M
Multimodal MRI biomarkers of small vessel disease for older persons with and without dementia.UH3NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2018 to 2020
$3.5M
Development of MRI microvascular biomarkers in cognitive impairment and dementiaUH3NS100588 · NINDS · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S., LU, HANZHANG · 2018 to 2020
$3.5M
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohortUH3NS100606 · NINDS · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, WILCOCK, DONNA M · 2018 to 2020
$3.4M
Multiethnic Validation of VCID Biomarkers in South TexasU01NS125513 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FORNAGE, MYRIAM, SATIZABAL, CLAUDIA L · 2023 to 2025
$3.3M
NIA NIH HHS P20 AG068077NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072946NIA NIH HHS R01 AG080821NIH HHS S10 OD023573NIH HHS S10 OD025313NINDS NIH HHS U01 NS100599NINDS NIH HHS U01 NS125513NINDS NIH HHS U24 NS100591NINDS NIH HHS UF1 NS100598NINDS NIH HHS UF1 NS100599NINDS NIH HHS UF1 NS100614NINDS NIH HHS UF1 NS125488NINDS NIH HHS UH2 NS100588NINDS NIH HHS UH2 NS100598NINDS NIH HHS UH2 NS100599NINDS NIH HHS UH2 NS100605NINDS NIH HHS UH2 NS100606NINDS NIH HHS UH2 NS100608NINDS NIH HHS UH2 NS100614NINDS NIH HHS UH3 NS100588NINDS NIH HHS UH3 NS100599NINDS NIH HHS UH3 NS100605NINDS NIH HHS UH3 NS100606NINDS NIH HHS UH3 NS100608
6 · The paper itself

Abstract

backgroundWhite matter hyperintensities (WMH) that occur in the setting of vascular cognitive impairment and dementia (VCID) may be dynamic increasing or decreasing volumes or stable over time. Quantifying such changes may prove useful as a biomarker for clinical trials designed to address vascular cognitive-impairment and dementia and Alzheimer's Disease.

objectiveConducting multi-site cross-site inter-rater and test-retest reliability of the MarkVCID white matter hyperintensity growth and regression protocol.

methodsThe NINDS-supported MarkVCID Consortium evaluated a neuroimaging biomarker developed to track WMH change. Test-retest and cross-site inter-rater reliability of the protocol were assessed. Cognitive test scores were analyzed in relation to WMH changes to explore its construct validity.

resultsICC values for test-retest reliability of WMH growth and regression were 0.969 and 0.937 respectively, while for cross-site inter-rater ICC values for WMH growth and regression were 0.995 and 0.990 respectively. Word list long-delay free-recall was negatively associated with WMH growth (p < 0.028) but was not associated with WMH regression.

conclusionsThe present data demonstrate robust ICC validity of a WMH growth/regression protocol over a one-year period as measured by cross-site inter-rater and test-retest reliability. These data suggest that this approach may serve an important role in clinical trials of disease-modifying agents for VCID that may preferentially affect WMH growth, stability, or regression.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDementia, VascularWhite MatterBiomarkersHumansMagnetic Resonance ImagingReproducibility of ResultsBiomarkersAgingAlzheimer’s diseasecerebrovascular diseasedementialongitudinalMarkVCIDsmall vessel ischemic diseasewhite matter hyperintensity

Identifiers

PMID37840499
PMCPMC11009792
OpenAlexW4387473806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.